VERDESO
LOE ApproachingNDATOPICALAEROSOL, FOAM
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERDESO is a topical aerosol foam product approved in 2006 by Almirall for dermatological use. The specific indication and mechanism of action are not publicly detailed in available data, but the formulation represents a specialized topical delivery system. The foam format enables efficient application to affected skin areas.
$0.032MPart D
LOE ApproachingDeclining
1.3 years to LOEMinimal commercial footprint with near-zero Part D penetration signals a niche or legacy product with small brand team and limited growth headroom.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on VERDESO at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.